Assessment of DNA damage in postmenopausal women under osteoporosis therapy

Basit Öğe Kaydı
dc.contributor.authorBayram, Merih
dc.contributor.authorSoyer, Canan
dc.contributor.authorKadioglu, Ela
dc.contributor.authorSardas, Semra
dc.date.accessioned2020-06-25T17:43:29Z
dc.date.available2020-06-25T17:43:29Z
dc.date.issued2006
dc.descriptionSardas, Semra/0000-0001-5456-8636
dc.description.abstractObjective: The following study was designed to examine possible DNA damage levels in peripheral blood leukocytes, using the alkaline Comet assay, isolated from postmenopausal women undergoing osteoporosis treatment. Study Design: Thirty-two postmenopausal women were randomized into two groups of 16. A dosage of 2.5 mg/day of tibolone (Livial) and 10 mg/day of alendronate sodium (Fosamax) were administered to Group 1 over a 12-month period while Group 2 took 10 mg/day of alendronate alone over the same period. The control group consisted of 16 postmenopausal women who did not receive any treatment. Genotoxicity was assessed by the standard method of alkaline Comet assay. Results: When the results of the study groups were compared with those of the control group, significant differences in terms of DNA damage levels were found (p < 0.05). However, no difference was detected between Groups 1 and 2 (p > 0.05). Conclusion: Although, no statistical difference in terms of DNA damage levels between tibolone plus alendronate as opposed to alendronate alone was found, an increase in DNA damage levels was observed in Groups 1 and 2 compared with the control group. Consequently, it can be asserted that the frequency of DNA damage in postmenopausal women with osteoporosis increases under alendronate treatment with or without tibolone. (C) 2006 Elsevier Ireland Ltd. All rights reserved.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.1016/j.ejogrb.2006.01.027
dc.identifier.endpage230en_US
dc.identifier.issn0301-2115
dc.identifier.issn1872-7654
dc.identifier.issue2en_US
dc.identifier.pmid16504368
dc.identifier.scopus2-s2.0-33746882155
dc.identifier.scopusqualityQ2
dc.identifier.startpage227en_US
dc.identifier.urihttps://doi.org10.1016/j.ejogrb.2006.01.027
dc.identifier.urihttps://hdl.handle.net/20.500.12587/3736
dc.identifier.volume127en_US
dc.identifier.wosWOS:000240483600013
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Science Bven_US
dc.relation.ispartofEuropean Journal Of Obstetrics & Gynecology And Reproductive Biology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectosteoporosisen_US
dc.subjectalendronateen_US
dc.subjecttiboloneen_US
dc.subjectcomet assayen_US
dc.subjectgenotoxicityen_US
dc.titleAssessment of DNA damage in postmenopausal women under osteoporosis therapyen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Assessment of DNA damage in postmenopausal women under osteoporosis therapy.pdf
Boyut:
124.91 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu